Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 8,429 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Glucose Metabolism Disorders Clear all

Conditions: Type 2 Diabetes
Interventions: INCB013739, Placebo comparator matching INCB013739, Metformin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Artesia, California • Calabasas, California + 54 more

Conditions: Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions: Allograft; Other
Lead sponsor: Tides Medical; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Fresno, California • Los Angeles, California • Vista, California + 5 more

Conditions: Diabetes Mellitus
Interventions: T-PLUS Meter; Device
Lead sponsor: Ascensia Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Atherosclerosis
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metabolic Syndrome
Interventions: Liraglutide, Exercise training, Liraglutide + Exercise training; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 55 Years
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes
Interventions: ITCA 650 60 mcg/day, sitagliptin; Drug
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Hayward, California

Conditions: Diabetes
Interventions: Exendin (9-39), acyl ghrelin, saline; Drug
Lead sponsor: David Dalessio; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Gestational Diabetes, Gestational Diabetes Mellitus in Pregnancy
Interventions: Staff -Educational training; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gestational Diabetes Mellitus
Interventions: Exendin 9-39; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea; Drug · Other
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 93
States / cities: Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more

Conditions: Diabetes
Interventions: Reciprocal Diabetes Peer Support Program, Nurse Case management, group outpatient counseling visits; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes Mellitus, Hypoglycemia
Interventions: Continuing Glucose Monitor System; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus
Interventions: BlueStar 10; Device
Lead sponsor: Welldoc; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Glimepiride, Diet, Exercise; Drug · Behavioral
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 46
States / cities: Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more

Conditions: Pre Diabetes, Obesity
Interventions: MapTrek, Fitbit; Behavioral · Device
Lead sponsor: Philip Polgreen; Other
Eligibility: 21 Years to 80 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Coralville, Iowa

Conditions: Obesity, PreDiabetes
Interventions: ADI-PEG20, Placebo; Biological · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 22 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Coronary Arteriosclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: controlled-release oral alpha-lipoic acid; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Overweight , Obesity
Interventions: Stair-Climbing Exercise Snacks; Behavioral
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes, Gestational
Interventions: Text-message reminder; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Type 2 Diabetes
Interventions: Basal insulin, Dexcom Continuous Glucose Monitoring (CGM); Drug · Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Gestational Diabetes, Pregnancy, Obesity
Interventions: Not listed
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Type 2 Diabetes
Interventions: Insulin glargine injection, metformin, Placebo pill; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

User Performance of the Thunder Plus BGMS

Longitudinal Study in Perimenopausal Women With Risk Factors for Atherosclerosis

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Chronic Inflammation and Exercise Responsiveness

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

Ghrelin Effect on Beta Cell Function in Health and Disease

Clinic to Community Connections - Broader Distribution

Islet Function in Gestational Diabetes

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Improving Insulin Therapy With Enhanced Care Management

Role of CGMS Usage in Predicting Risk for Hypoglycemia

A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes

ADI-PEG20, Obesity and Prediabetes

Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease

Pilot Study on the Effect of Oral Controlled-Release Alpha-Lipoic Acid on Oxidative Stress in Adolescents With Type 1 Diabetes Mellitus

Two-Week Stair-Climbing Exercise Snacks and Metabolic Health in Adults With Overweight or Obesity: A Pilot Study

Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes

Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor

Oral Glucose Tolerance Testing After Gestational Diabetes

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes